BIOCRYST ANNOUNCES PUBLICATION OF ABSTRACTS ON FODOSINE TREATMENT

A A

BioCryst Pharmaceuticals has reported that three abstracts related to the clinical development of Fodosine (forodesine HCl), its product candidate for the treatment of certain leukemias and lymphomas, have been published Blood, the journal of the American Society of Hematology.

Fodosine is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase. The drug is currently in a Phase IIa trial for patients with T-cell leukemia and a combination IV and oral Phase I pharmacokinetic trial in healthy volunteers. Results of the Phase IIa and the Phase I pharmacokinetic trial will assist in the design of a planned combination IV and oral Phase IIb pivotal clinical trial in patients with T-cell leukemia.